Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims 
Vale Reports $3.8 Billion Q4 Net Loss Amid Nickel Asset Impairment and Samarco Provisions 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy 
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed 
Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment 
Lyft Shares Slide After Weak Q1 Profit Forecast and Surprise 2025 Operating Loss 
Michael Kors Marks 45 Years at New York Fashion Week with Fall/Winter Collection Showcase 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
Dublin, Nov. 09, 2017 -- The "From R&D Investment to Externalization: Where is the Pharma Industry Maximizing Value?" report has been added to Research and Markets' offering.
Pharmaceutical companies are attempting to maximize value from all angles, including internal investment in R&D and externalization via deal-making. The growth in these two models has had an impact on both revenue derived from internally developed products, as well as externalized drugs.
Key Topics Covered:
1 EXECUTIVE SUMMARY
2 OVERALL TRENDS
3 R&D INVESTMENT TRENDS
- Overall R&D Investment trends
- Peer set R&D investment trends
- R&D productivity
- Bibliography
4 BIG PHARMA LICENSING TRENDS
- Alliance volume and value
- In-licensing and out-licensing
- Phase trends
- Therapy area trends
- Bibliography
5 REVENUE EXTERNALIZATION TRENDS
- Higher volume of unpartnered drugs, but partnered candidates are growing faster
- Externalized revenue growth due to M&A, co-developed drugs, and acquired products
- Peer set externalized revenue trends
- Higher average per-drug revenue expected for externalized products
- Bibliography
6 APPENDIX
- Scope
- Methodology
For more information about this report visit https://www.researchandmarkets.com/research/f39gpt/from_randd
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Pharmaceuticals
